Loading
companiesCompany
5AM Ventures
A venture firm with offices in San Francisco and Boston that funds early-stage drug companies and also runs a public-market fund. Its cancer investments include the cell therapy company Artiva, the protein degrader pioneer Arvinas and Enliven Therapeutics.
Overview
5AM Ventures describes itself as 'a leading investment firm focused on funding and building next-generation life sciences companies'. Its venture strategy 'primarily invests in private therapeutic companies' with an emphasis on Series A, its 4:59 Initiative incubates academic science to reach Series A-ready proof of concept, and the 5AM Opportunities strategy invests in small and mid-cap public and later-stage private biotechs. Oncology examples on its portfolio page include Aprea (mutant p53 reactivation, IPO 2019), Artiva Biotherapeutics (allogeneic natural killer cell therapies for cancer, IPO 2024), Arvinas (targeted protein degradation with applications in cancer, IPO 2018), Cidara (viral and oncologic diseases), Deverra (off-the-shelf cellular immunotherapies) and Enliven Therapeutics (precision oncology small molecules).
Portfolio (1)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Radionetics Oncology San Diego, CA, US | Startup | radiopharma | Series A 2024, $53M |
Notes
top- Founding year not stated on fetched pages, so omitted. Office cities (San Francisco and Boston) follow the task hint; the fetched pages did not list addresses.
Similar pages
- CompanyFrazier Life Sciences
Shares Radionetics Oncology, Enliven Therapeutics and the tag vc.
- CompanyDCVC
Shares Radionetics Oncology and the tag vc.
- CompanyVenrock
Shares Enliven Therapeutics and the tag vc.
- CompanyRA Capital Management
Shares Enliven Therapeutics and the tag vc.